Goals for Lead Optimization

Once the most promising hit compound is identified as the lead compound, it will enter the lead compound optimization and preclinical development stages of early drug development. Lead optimization is a complex iterative process that involves converting a series of compounds into preclinical candidates. This is considered to be a key point in the development of novel drugs, and also a key process for identifying drug candidates to enter clinical trials. The main goal of this stage is to improve the physical and chemical properties of the hit compounds through a series of screening and testing experiments. These experiments include stability, potency, efficacy, safety, etc. The higher the quality of the preclinical drug candidate, the higher the probability of successfully progressing into clinical development.

Services Overview

At Ace Therapeutics, we provide each client with a team that has been specialized to maximize our efficiency in delivering drug candidates from our lead series, thereby helping our clients achieve high-quality service and results. Drawing on in-depth knowledge of our ophthalmic disease domain as well as live animal models (rat, mouse, rabbit, and zebrafish), our scientists optimize the selection process to ensure robust results.

How do We Lead Optimization?

Ace Therapeutics has a technical team of chemists, pharmacologists and ADME/DMPK scientists to meet the requirements of preclinical drug candidates in ophthalmology. With our in vitro and in vivo facilities, we can support ADME and custom studies by evaluating lead drug metabolites and associated biomarkers. Additionally, we minimize the number of assays required by assessing clinical pharmacokinetics early in drug development, resulting in superior preclinical candidates. By doing this, your drug candidate will be delivered in as few iterations as possible, saving you time and money.

Ace Therapeutics assists our clients in identifying and optimizing lead compounds. Our services include but are not limited to:

• In Vitro Safety and Pharmacology Studies
• In Vitro ADME
• In Vitro Toxicity Test
• In Vivo PK Studies
• Pharmacology and Pharmacodynamics Research

Explore Our Capabilities

Optimization of lead compounds involves in vitro and in vivo evaluation of their properties. We have a skilled team dedicated to serving our customers, using our combination of in vitro and in vivo models, combined with our state-of-the-art analytical platform to provide you with the most cost-effective and effective solutions to reach your research milestones. We are proud of several capabilities in the field of lead optimization, including but not limited to.

• Potency and selectivity assessment in cell-based assays.
• Design, synthesis and optimization of medicinal chemistry SAR and lead series.
• PK and PK/PD studies in rodents, lagomorphs or zebrafish, including metabolite identification and quantification.
• In vitro and in vivo assessment of metabolism, off-target activity.
• Structural biology assessment (structural characterization, aggregation state, target/ligand interactions).
• Identification of biomarkers in animal and human body fluids.
• Scaled-up synthesis of small-molecule compounds.
• Chemistry support for synthesis optimization.
• Multidisciplinary support in structural biology, cell biology and proteomics.

Benefit from our state-of-the-art facilities, extensive expertise and decades of experience in lead optimization. Excellent track record of our experts when it comes to ophthalmic molecule lead optimization. We help clients obtain breakthrough medicines through methods of analytical development and screening, computer-aided drug design and pharmaceutical sciences. At Ace Therapeutics, we provide excellent ophthalmology preclinical drug candidates to pave the way for your project to enter the clinic. If you want to know more about lead optimization or have any special needs, please do not hesitate to contact us.

• Target ID and Validation Services for Small Molecule Ophthalmic Drug
• Hit Identification Services for Small Molecule Ophthalmic Drug
• Hit to Lead Services for Small Molecule Ophthalmic Drug

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit